Drug
Grn163l
Grn163l: highest development phase Phase 1, developed by Geron Corporation. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Geron Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| GRN163L NCT00124189 | Phase 1 | Chronic Lymphoproliferative Diseases |
| GRN163L NCT00732056 | Phase 1 | Breast Cancer |
Latest
No recent events.
Follow Grn163l on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.